News - Financing risk management - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

Company news

Efung News | HighLight Pharma’s JAK1/TYK2 Inhibitor Proposed for Breakthrough Therapy Designation in

June 24, 2026 – HighLight Pharma's JAK1/TYK2 inhibitor TLL-018 has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) program for the treatment of rheumatoid arthritis.Founded in 2017, HighLight Pharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. Its lead asset, TLL-018, is a highly selective JAK1/TYK2 inhibitor. The drug is currently undergoing two pivotal Phase III registrational trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), both of which have met their primary endpoints. The company is also exploring multiple additional autoimmune indications. Its pipeline further includes TLL-041, a brain-penetrant JAK1/TYK2 inhibitor, as well as NLRP3 inhibitors and a highly selective brain-penetrant LRRK2 inhibitor.Efung Capital participated in HighLight Pharma's financing rounds in 2020 and 2021. Looking ahead, Feng Capital will continue to deepen its dual-drive strategy of "industrial cap...

2026 - 06 - 25
Efung News | The First and Only One in China! RuiJing Bio’s NGS-Based Thyroid Cancer Molecular Detec

On June 23, 2026, Shanghai RuiJing Biotechnology Co., Ltd. (hereinafter referred to as "RuiJing Bio") independently developed the "Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit (Joint Probe Anchoring Polymerization Sequencing Method)" officially received a Class III Medical Device Registration Certificate (Registration No.: 20263401321) issued by the National Medical Products Administration (NMPA). As the first and only NGS-based thyroid cancer molecular detection kit approved in China, this certification fills a critical gap in compliant clinical NGS applications, offering clinicians a more diversified and comprehensive precision diagnostic solution, and marking the official entry of thyroid cancer molecular diagnostics into the NGS era.In recent years, thyroid cancer has become the fastest-growing malignancy globally and in China. According to the latest domestic epidemiological data, the number of new thyroid cancer cases now ranks second a...

2026 - 06 - 24
Efung News | ProteLight Pharma’s World’s First Granulin-Class Antimicrobial Peptide Drug

ProteLight Pharma announced that its independently developed China’s first Class 1 innovative granulin-class antimicrobial peptide drug, Puyike® (Peleganan Spray), received approval for market launch from the National Medical Products Administration (NMPA) on June 17, 2026. The drug is primarily indicated for the treatment of secondary wound infections such as burns and scalds.Peleganan Spray is a First-in-class (FIC) new drug independently developed based on ProteLight Pharma’s Antimicrobial Peptide Drug Design Platform (AMPDDP). The successful approval marks the global debut of the first granulin-class anti-infective therapeutic.The approval of Peleganan Spray for treating secondary wound infections including burns and scalds is supported by data from multiple pivotal clinical studies.Efung Capital participated in ProteLight Pharma’s financing round in 2025. Looking ahead, Efung Capital will leverage its professional investment expertise and ecosystem empowerment capabilities in...

2026 - 06 - 22
Efung News | Continuously Doubling Down on the World's First Red Blood Cell Innovation Track! Ef

Recently, Westlake Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as "Westlake Therapeutics") announced the completion of a new financing round exceeding RMB 100 million. This round was co-led by Beijing Shijingshan Modern Innovation Industry Development Fund Co., Ltd. ("Shijingshan Modern Innovation Industry Fund") and Ruili Synthetic Biology Fund, with follow-on participation from renowned industrial investors. Existing shareholders including Efung Capital, Huafang Capital, and Sequoia China continued to inject additional capital.The proceeds from this financing round will be primarily utilized to advance the pipeline development of the company's red blood cell drug platform in therapeutic areas such as oncology and autoimmune diseases, accelerate the clinical validation and regulatory filing of core products, and further strengthen R&D, manufacturing, and industrialization capabilities.Efung Capital participated in Westlake Therapeutics' f...

2026 - 06 - 18
Efung Honor | Efung Capital Named Among 36Kr's 2026 "China Equity Investment Industry Venture Capita

Recently,36Kr's 2026 annual"China Equity Investment Industry Investment Institutions" series rosterwas officially released, with Efung Capital honored as one of the"China Equity Investment Industry Venture Capital Institutions,"and the Waves·2026 "36 Under 36" rosterwas officially announced,with Efung Capital's Zhu Pai named to the list.At the outset of 2026, McKinsey made a judgment in its global private market report: Alpha is no longer found—it is made. Persistently low interest rates, ever-inflating valuation multiples, and readily available cheap financing—the old levers that once amplified profits—are disappearing one by one.The story in China's market is even more complex. The source of capital has shifted: as US-dollar funds recede, state-owned capital and industrial capital have taken over pricing power and the authority to write the rules. The exit channels have also changed—IPOs are no longer a panacea, and M&A and secondary...

2026 - 06 - 17
Efung Mingyuan Seed Fund Lands in Guangming, Focusing on "20+8" Biomedical and High-End Medical Devi

June 10, 2026Shenzhen Efung Mingyuan Seed Venture Investment Partnership (Limited Partnership), established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its business registration.This milestone marks a critical step forward for Efung Capital in ultra-early-stage investment, and more importantly, signals that Shenzhen's "20+8" industrial clusters have welcomed a new seed fund force that deeply integrates "industrial capital with cutting-edge scientific research."01Precisely Targeting the "20+8" Industrial Clusters, Securing "Source Water" for InnovationWith a total scale of RMB 127.5 million, the Efung Mingyuan Seed Fund is dedicated to identifying and investing in seed-stage projects, covering ultra-early-stage startups and research projects that have not yet been incorporated. The fund strategically focuses on the biomedical and health-related sectors that are prioritized and e...

2026 - 06 - 16

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务